Evidence map›Paper›PMID 39521434›Full record

Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC.

Jhanelle E Gray, Michael Schenker, Mehmet Ali Nahit Şendur, Viktoriya Leonova, Dariusz Kowalski, Terufumi Kato, Rashida Orlova, James Chih-Hsin Yang, Adrian Langleben, Arnold Pilz and 8 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03976323 (A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03976323 phase3completednot on this map

A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2019 to 2026Enrolled1,003ConditionsCarcinoma, Nonsquamous Non-small-cell LungArmsPembrolizumab, Pemetrexed, Carboplatin, Cisplatin, Olaparib
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Jhanelle E GrayMoffitt Cancer Center, Tampa, Florida. Electronic address: jhanelle.gray@moffitt.org.
Michael SchenkerSf Nectarie Oncology Center Craiova and the University of Medicine and Pharmacy of Craiova, Craiova, Romania.
Mehmet Ali Nahit ŞendurAnkara Yıldırım Beyazıt University and Department of Oncology, Ankara Bilkent City Hospital, Ankara, Türkiye.
Viktoriya LeonovaRegional Clinical Oncology Center, Kharkiv, Ukraine.
Dariusz KowalskiThe Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Terufumi KatoKanagawa Cancer Center, Yokohama, Japan.
Rashida OrlovaSt. Petersburg State University, St. Petersburg State Budgetary Healthcare Institution City Clinical Oncological Dispensary, Saint-Petersburg, Russia.
James Chih-Hsin YangNational Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan.
Adrian LanglebenDepartment of Oncology, St. Mary's Hospital, McGill University, Montreal, Quebec, Canada.
Arnold PilzLudwig Boltzmann Institute for Lung Health, Vienna, Austria.
Andrei UngureanuS. C. Radiotherapy Center Cluj, Cluj, Romania.
Milena Perez MakInstituto do Câncer do Estado de São Paulo, São Paulo, Brazil.
Flavia De AngelisIntegrated Health and Social Services Centres, Montérégie Centre, Greenfield Park, Quebec, Canada.
Himani AggarwalMerck & Co., Inc., Rahway, New Jersey.
Zachary ZimmerMerck & Co., Inc., Rahway, New Jersey.
Bin ZhaoMerck & Co., Inc., Rahway, New Jersey.
Mark ShamounMerck & Co., Inc., Rahway, New Jersey.
Tae Min KimSeoul National University Hospital, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPoly (adenosine diphosphate-ribose) inhibitors, including olaparib, upregulate programmed cell death ligand 1, which may increase the efficacy of anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapies.

methodsIn the phase 3 KEYLYNK-006 trial (NCT03976323), eligible adults with previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations who had complete response, partial response, or stable disease after induction therapy with four cycles of pembrolizumab 200 mg every three weeks, pemetrexed 500 mg/m

resultsOf 1003 patients who received induction therapy, 672 (67.0%) were randomized to pembrolizumab plus olaparib (n = 337) or pembrolizumab plus pemetrexed (n = 335) in the intention-to-treat population. Median follow-up at FA was 39.9 (range: 28.1-51.5) months. At interim analysis 2, the median (95% confidence interval [CI]) PFS was 7.1 (5.6-8.7) months versus 8.3 (6.9-11.5) months in the olaparib versus pemetrexed groups (hazard ratio = 1.12, 95% CI: 0.92-1.36, p = 0.87). At FA, the median (95% CI) OS was 20.7 (18.0-24.8) months versus 23.0 (19.0-26.4) months (hazard ratio = 1.04, 95% CI: 0.87-1.25, p = 0.6649). Grade 3 to 5 maintenance treatment-related adverse events occurred in 26.1% versus 30.1% of patients, respectively.

conclusionPembrolizumab plus maintenance olaparib did not improve PFS or OS versus pembrolizumab plus pemetrexed in previously untreated metastatic nonsquamous NSCLC without targetable genetic alterations.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPemetrexedPhthalazinesPiperazinesAdultAgedFemaleHumansMaintenance ChemotherapyMaleMiddle AgedSurvival RateAntibodies, Monoclonal, HumanizedolaparibpembrolizumabPemetrexedPhthalazinesPiperazinesKEYLYNK-006Non-squamous non‒small-cell lung cancerOlaparibPembrolizumabPemetrexed

Identifiers

PMID39521434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.